{"name":"Codexis","slug":"codexis","ticker":"CDXS","exchange":"NASDAQ","domain":"codexis.com","description":"Codexis, Inc. is a protein engineering company that develops enzymes for pharmaceutical, food and medical applications.","hq":"Redwood City, CA","founded":0,"employees":"146","ceo":"Stephen Dilly","sector":"Enzyme Engineering / Biocatalysis","stockPrice":2.6,"stockChange":0.1,"stockChangePercent":4,"marketCap":"$237M","metrics":{"revenue":138590000,"revenueGrowth":102.1,"grossMargin":23.8,"rdSpend":52307000,"netIncome":-43974000,"cash":65140000,"dividendYield":0,"peRatio":-7,"fiscalYear":"FY2022"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"Atorvastatin patent cliff ($10.4B at risk)","drug":"Atorvastatin","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Codexis Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Codexis reported its fourth quarter and full year 2023 financial results, with revenue of $23.4 million and a net loss of $14.1 million.","drugName":"","sentiment":"neutral"},{"date":"2023-11-15","type":"deal","headline":"Codexis Announces Collaboration with Merck to Develop New Biocatalytic Processes","summary":"Codexis announced a collaboration with Merck to develop new biocatalytic processes for the production of APIs and intermediates.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-03-15","type":"earnings","source":"simplywall.st","summary":"Codexis (CDXS) Is Up 30.9% After Merck-Fueled Q4 Profit Beat And 2026 Revenue Guidance - Has The Bull Case Changed? - simplywall.st","headline":"Codexis (CDXS) Is Up 30.9% After Merck-Fueled Q4 Profit Beat And 2026 Revenue Guidance - Has The Bull Case Changed?","sentiment":"positive"},{"url":"https://news.google.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?oc=5","date":"2026-03-14","type":"earnings","source":"simplywall.st","summary":"Assessing Codexis (CDXS) Valuation After Strong Earnings And New ECO Synthesis siRNA Agreement - simplywall.st","headline":"Assessing Codexis (CDXS) Valuation After Strong Earnings And New ECO Synthesis siRNA Agreement","sentiment":"positive"},{"url":"https://news.google.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?oc=5","date":"2026-03-12","type":"earnings","source":"simplywall.st","summary":"Codexis (CDXS) Q4 Profit Turns Positive EPS Into Test Of Turnaround Narrative - simplywall.st","headline":"Codexis (CDXS) Q4 Profit Turns Positive EPS Into Test Of Turnaround Narrative","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxOSVAtRDJXUFo1eTRnNlhhdHBRRmVPTUcteXVRZktwenhCR1dia0ZhNGdpZlk3X2tpZmQxUU5tUHlIZlVJZ2o4and1SEF0OGhYbGJBTl95WEo0OUR0bW5hVkdjM1pDWFd6bWZTTFV5UjNvZVRDRHBkMEhmOGlzdWYtRDc0ZjRqNUxOcURLRWdqaWpwRmp0ZUpXdm8xLWdfbDRJNjBvMHM0SjNYUXp0cTR0dmRySnJGTUxZT2xF?oc=5","date":"2026-03-11","type":"pipeline","source":"Benzinga","summary":"12 Health Care Stocks Moving In Wednesday's After-Market Session - Acurx Pharmaceuticals (NASDAQ:ACXP), A - Benzinga","headline":"12 Health Care Stocks Moving In Wednesday's After-Market Session - Acurx Pharmaceuticals (NASDAQ:ACXP), A","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxQREZfU0tTLWtRZ2ExNGlpbjcxckNnY0JTeE90c1RUYVlBUXVZMnZuUzgyUk1MLWtMUFRNdkF4c1BWa0dFbnFyeHVxaElEMDR0X2ZJaVFWeWNpRmt0V2ItSzkxZUlkTFc1RmItM1ZkSm00eVhfSnlRamFnT1J3bVl5RWxWdFFkWk1nNGlhWWxiWTU2VTB2bGRKZGpZanFldmR0bGpLMjJDSEJ0d3pjY3d3dnE1bjVpdTQ?oc=5","date":"2026-03-11","type":"earnings","source":"Stock Titan","summary":"Codexis swings to Q4 profit as Merck deal lifts revenue and funds RNAi push - Stock Titan","headline":"Codexis swings to Q4 profit as Merck deal lifts revenue and funds RNAi push","sentiment":"neutral"},{"date":"2026-03-11","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-11","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxQajdnUk1TSU9fRndTSXRZT0xtSzRfSUl3bWJsWEZQazJmY25WZXpxazhHZ29RM0VYZXA4OVZZZ3pvLU16ZUxqZHZlMjVwNXdrUnJjd0xnR0NqcW40WkVEbEc4Vm1jMlNycUtwLUZZRjdfUlh1c2o3N3VEbDZYMU1HSUtKUGI1aGJpbnpSbzhYSnFqSWduU29venl0bjhkd1NrMmc5RHlRWHZPS1ZLN2c0?oc=5","date":"2026-03-04","type":"deal","source":"in.investing.com","summary":"Codexis signs deal to produce siRNA for pharma partner By Investing.com - in.investing.com","headline":"Codexis signs deal to produce siRNA for pharma partner By Investing.com","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxPSENmeWN2WFFGNXgzR205SGlkWFVJOE9WWTRiQzJldm0wTEI4ZXByOXNTVGo1ZkFMamRqWkppbFlZVDl5ZzZUb2pkWmhabXVJc0o4NFI3a2JVbWdLa0dBZGFrVlJFZFpqNWZPY2pNRzR6OU1uZ0RaUlYxb1pObmREb2NseEt5djhoc29xQ3h0cWV6eFJxMF8zRnk1LWlwU1BDUFFBTTg1QkNWbzF1YkhrejFnQW9paTA1RGVOOEtWdw?oc=5","date":"2026-03-04","type":"deal","source":"GuruFocus","summary":"Codexis (CDXS) Partners for siRNA Manufacturing in Cardiovascula - GuruFocus","headline":"Codexis (CDXS) Partners for siRNA Manufacturing in Cardiovascula","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiTkFVX3lxTE9pY0xLRmtmUHUtN05XWklmUjVNMEE4a1hzbW9qVFg2cE13dTl1bFNhUXA0cndsa3ZUNWtsNkxnQWhzZjUtRlV4bExkd1lvZw?oc=5","date":"2025-10-29","type":"earnings","source":"Stock Titan","summary":"Latest CDXS News - Codexis Reports Fourth Quarter and Fiscal Y... - Stock Titan","headline":"Latest CDXS News - Codexis Reports Fourth Quarter and Fiscal Y...","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-05-17","type":"earnings","source":"simplywall.st","summary":"Codexis, Inc. (NASDAQ:CDXS) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates - simplywall.st","headline":"Codexis, Inc. (NASDAQ:CDXS) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUEFVX3lxTE1mSnd5UnFTc3dUcllZOGVncmY5TVAxaUtSMW9QbDN3XzlCT0M5T3llV2l6aVNRSHRXQ3JmMHd6N2pnRTRkZElaVFR1Q184NmdU?oc=5","date":"2021-09-14","type":"pipeline","source":"The Motley Fool","summary":"Codexis - CDXS - Stock Price & News - The Motley Fool","headline":"Codexis - CDXS - Stock Price & News","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMia0FVX3lxTE01N3B4ZXFfVGFCTG01RFVXYWQwRFlTb09vaEdBQkd4VFNDV0xKZ3VhN1FxT2tadVkwb0h5U2hFdFJNUk1NU2V1ZkFoNkdQd0VEQzlmeWo3QXFIMm1pLWJ3bjZQOUdaWEE5MV9v?oc=5","date":"2020-08-10","type":"pipeline","source":"Nanalyze","summary":"A Pure-Play Protein Engineering Stock - Nanalyze","headline":"A Pure-Play Protein Engineering Stock","sentiment":"neutral"}],"patents":[{"drugName":"Atorvastatin","drugSlug":"lipitor","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":10400000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Amyris","Ginkgo Bioworks","Novozymes"],"therapeuticFocus":["Cardiovascular","Metabolic Disorders"],"financials":{"source":"sec_edgar+yahoo","revenue":138590000,"revenuePeriod":"2022-12-31","revenueHistory":[{"value":138590000,"period":"2022-12-31"},{"value":104754000,"period":"2021-12-31"},{"value":104754000,"period":"2021-12-31"},{"value":69056000,"period":"2020-12-31"},{"value":69056000,"period":"2020-12-31"}],"grossProfit":61049000,"grossProfitHistory":[{"period":"2025-12-31","value":61049000},{"period":"2024-12-31","value":43057000},{"period":"2023-12-31","value":57334000},{"period":"2022-12-31","value":100557000}],"rdSpend":52307000,"rdSpendHistory":[{"period":"2025-12-31","value":52307000},{"period":"2024-12-31","value":46263000},{"period":"2023-12-31","value":58885000},{"period":"2022-12-31","value":80099000}],"sgaSpend":47074000,"operatingIncome":-38332000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-38332000},{"period":"2024-12-31","value":-58354000},{"period":"2023-12-31","value":-54801000},{"period":"2022-12-31","value":-31714000}],"netIncome":-43974000,"netIncomeHistory":[{"period":"2025-12-31","value":-43974000},{"period":"2024-12-31","value":-65276000},{"period":"2023-12-31","value":-76240000},{"period":"2022-12-31","value":-33592000}],"eps":-0.89,"epsHistory":[{"period":"2024-12-31","value":-0.89},{"period":"2023-12-31","value":-1.12},{"period":"2022-12-31","value":-0.51},{"period":"2021-12-31","value":-0.33}],"cash":50793000,"cashHistory":[{"period":"2025-12-31","value":50793000},{"period":"2024-12-31","value":19264000},{"period":"2023-12-31","value":65116000},{"period":"2022-12-31","value":113984000}],"totalAssets":147797000,"totalLiabilities":97268000,"totalDebt":73208000,"equity":50529000,"operatingCashflow":-19376000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-19376000},{"period":"2024-12-31","value":-49410000},{"period":"2023-12-31","value":-52638000},{"period":"2022-12-31","value":11284000}],"capex":-4471000,"capexHistory":[{"period":"2025-12-31","value":-4471000},{"period":"2024-12-31","value":-4305000},{"period":"2023-12-31","value":-4418000},{"period":"2022-12-31","value":-8307000}],"freeCashflow":-23847000,"dividendsPaid":null,"buybacks":null,"employees":146,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":11185000,"ebit":11215000,"ebitda":11215000,"period":"2025-12-31","revenue":38915000,"epsBasic":0.11,"netIncome":9601000,"rdExpense":11721000,"epsDiluted":0.11,"grossProfit":36872000,"operatingIncome":13966000},{"sga":11217000,"ebit":-18315000,"ebitda":-16221000,"period":"2025-09-30","revenue":8601000,"epsBasic":-0.22,"netIncome":-19615000,"rdExpense":13868000,"epsDiluted":-0.22,"grossProfit":6136000,"operatingIncome":-18949000},{"sga":12317000,"ebit":-12278000,"ebitda":-10212000,"period":"2025-06-30","revenue":15328000,"epsBasic":-0.16,"netIncome":-13272000,"rdExpense":13775000,"epsDiluted":-0.16,"grossProfit":13230000,"operatingIncome":-12862000},{"sga":12355000,"ebit":-19735000,"ebitda":-17826000,"period":"2025-03-31","revenue":7543000,"epsBasic":-0.25,"netIncome":-20688000,"rdExpense":12942000,"epsDiluted":-0.25,"grossProfit":4811000,"operatingIncome":-20486000},{"sga":13048000,"ebit":-9906000,"ebitda":-9906000,"period":"2024-12-31","revenue":21460000,"epsBasic":-0.13,"netIncome":-10376000,"rdExpense":12099000,"epsDiluted":-0.13,"grossProfit":17806000,"operatingIncome":-7341000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":2.6,"previousClose":2.5,"fiftyTwoWeekHigh":3.87,"fiftyTwoWeekLow":0.96,"fiftyTwoWeekRange":"0.96 - 3.87","fiftyDayAverage":2.08,"twoHundredDayAverage":2.05,"beta":2.53,"enterpriseValue":235004416,"forwardPE":-7,"priceToBook":4.67,"priceToSales":3.03,"enterpriseToRevenue":3.01,"enterpriseToEbitda":-11.44,"pegRatio":0,"ebitda":-20550000,"ebitdaMargin":-26.3,"freeCashflow":-8476750,"operatingCashflow":-18728000,"totalDebt":72903000,"debtToEquity":168.6,"currentRatio":5.36,"returnOnAssets":-12.5,"returnOnEquity":-68.9,"analystRating":"1.8 - Buy","recommendationKey":"buy","numberOfAnalysts":6,"targetMeanPrice":6.58,"targetHighPrice":11,"targetLowPrice":2,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":7.4,"institutionHeldPercent":74.5,"sharesOutstanding":90896567,"floatShares":72979945,"sharesShort":4675179,"shortRatio":3.31,"shortPercentOfFloat":5.1,"epsTrailing":-0.35,"epsForward":-0.37,"revenuePerShare":0.88,"bookValue":0.56,"officers":[{"age":58,"name":"Dr. Alison  Moore Ph.D.","title":"President, CEO & Director"},{"age":58,"name":"Ms. Georgia L. Erbez","title":"CFO & Chief Business Officer"},{"age":null,"name":"Dr. Stefan  Lutz Ph.D.","title":"Chief Scientific Officer"},{"age":82,"name":"Senator Byron L. Dorgan M.B.A.","title":"Consultant"},{"age":null,"name":"Mr. Britton  Jimenez","title":"Senior Vice President of Sales & Marketing"},{"age":null,"name":"Ms. Karen  Frechou-Armijo","title":"Senior VP & Head of Human Resources"},{"age":null,"name":"Mr. John  Schiffhauer","title":"Senior Vice President of Intellectual Property"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.codexis.com","phone":"650 421 8100"}}